chr1-17054017-C-T
Variant summary
Our verdict is Pathogenic. Variant got 20 ACMG points: 20P and 0B. PVS1PS1_ModeratePM2PP5_Very_Strong
The NM_003000.3(SDHB):c.3G>A(p.Met1?) variant causes a start lost change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_003000.3 start_lost
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 20 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SDHB | ENST00000375499.8 | c.3G>A | p.Met1? | start_lost | Exon 1 of 8 | 1 | NM_003000.3 | ENSP00000364649.3 | ||
SDHB | ENST00000466613.2 | n.15G>A | non_coding_transcript_exon_variant | Exon 1 of 3 | 2 | |||||
SDHB | ENST00000485515.5 | n.-10G>A | upstream_gene_variant | 5 | ENSP00000519322.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:3
- -
Initiation codon variant in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Identified in multiple individuals with a personal and/or family history of SDHB-related tumors in published literature (Neumann et al., 2009; Piccini et al., 2012; Sjursen et al., 2013; Bayley et al., 2020; Main et al., 2020); This variant is associated with the following publications: (PMID: 19351833, 23407919, 31492822, 32688340, 24096523, 22241717, 27279923) -
SDHB: PS4, PM2, PS1:Moderate, PVS1:Moderate -
Paragangliomas 4 Pathogenic:2
This variant results in the loss of the translation start codon (methionine at codon 1) of the SDHB gene. This variant is expected to disrupt the expression of the full-length SDHB protein. The next in-frame methionine occurs at codon 58, but it is not known if a functional SDHB protein product can be produced using p.Met58 as an alternative translation start site. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with pheochromocytoma/paraganglioma (PMID: 19351833, 22241717, 23407919, 27279923, 27279923, 32688340). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic. -
This variant is considered pathogenic. This variant is located within the gene translation start codon (p.Met1?) and is predicted to result in abnormal protein translation. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID:28503760, 32688340, 24096523, 28374168]. -
Hereditary pheochromocytoma-paraganglioma Pathogenic:2
The following ACMG criteria have been used in classification: PM2_SUP; PVS1_MOD; PS4; PS1 -
This variant results in the loss of the translation start codon (methionine at codon 1) of the SDHB gene. This variant is expected to disrupt the expression of the full-length SDHB protein. The next in-frame methionine occurs at codon 58, but it is not known if a functional SDHB protein product can be produced using p.Met58 as an alternative translation start site. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with pheochromocytoma/paraganglioma (PMID: 19351833, 22241717, 23407919, 27279923, 27279923, 32688340). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic. -
Pheochromocytoma Pathogenic:1
- -
Pheochromocytoma;C0238198:Gastrointestinal stromal tumor;C1861848:Paragangliomas 4 Pathogenic:1
This sequence change affects the initiator methionine of the SDHB mRNA. The next in-frame methionine is located at codon 58. This variant is not present in population databases (ExAC no frequency). Disruption of the initiator codon has been observed in individuals with paragangliomas, pheochromocytomas and renal cell carcinomas (PMID: 19351833, 22241717, 23407919, 23512077, 24096523, 25047027, 27279923, 28490599, 29951630). ClinVar contains an entry for this variant (Variation ID: 428932). This variant disrupts the p.Arg46 amino acid residue in SDHB. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12618761, 14500403, 15328326, 16314641, 17102082, 18362451, 23083876, 23282968). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.M1? variant (also known as c.3G>A), located in coding exon 1 of the SDHB gene, results from a G to A substitution at nucleotide position 3. This alters the methionine residue at the initiation codon. This alteration has been detected in multiple individuals with paraganglioma and/or pheochromocytoma (Neumann HP et al. Cancer Res. 2009 Apr;69(8):3650-6; Piccini V et al. Endocr. Relat. Cancer 2012 Apr;19(2):149-55; Sjursen W et al. Fam. Cancer 2013 Sep;12(3):529-35; Papathomas TG et al. Eur. J. Endocrinol. 2014 Jan;170:1-12). In addition to the clinical data presented in the literature, since sequence variations that modify the initiation codon (ATG) are expected to result in either loss of translation initiation, N-terminal truncation, or cause a shift in the mRNA reading frame, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at